NCT02784795 2025-08-21A Study of LY3039478 in Participants With Advanced or Metastatic Solid TumorsEli Lilly and CompanyPhase 1 Terminated94 enrolled 28 charts
NCT04521686 2025-06-27Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 MutationsEli Lilly and CompanyPhase 1 Active not recruiting200 enrolled
NCT02393248 2023-01-06Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)Incyte CorporationPhase 1/2 Terminated201 enrolled 71 charts